News

CSE New Diagnostic Stock Listing – Gemina Laboratories Ltd. (CSE: GLAB)

August 9, 2021 (Investorideas.com Newswire) The common shares of Gemina Laboratories Ltd. have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

Gemina Labs is a biosensor and diagnostic company with a unique and transformative proprietary biochemistry that significantly improves the performance of human and animal testings, including COVID-19, Influenza and other viruses.

__________________________

Les actions ordinaires de Humble & Fume Inc. ont ete approuvees pour inscription au CSE.

Les documents d’inscription et de divulgation seront disponibles sur www.thecse.com a la date de negociation.

Gemina Labs est une societe de biocapteurs et de diagnostic dotee d’une biochimie exclusive unique et transformatrice qui ameliore considerablement les performances des tests sur les humains et les animaux, y compris le COVID-19, la grippe et d’autres virus.

image

The Exchange is accepting Market Maker applications for GLAB. Please email: [email protected]

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: [email protected]

Pour toute question, pour obtenir de l’information supplementaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel a l’adresse: [email protected]

Investorideas.com is a Canadian Securities Exchange (CSE) Service Provider; Cannabis stocks, Blockchain stocks, Mining, E-sports, Energy, Biotech and more…

image

Check out Investorideas.com listing on the CSE service provider list. We offer discounts to CSE listed stocks!

The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004; the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets. http://thecse.com/

More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire – a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Follow Us on StockTwits

BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com – investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Buy a biotech guest post on Investorideas.com

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News

Next Article:

0 %